Patients with low baseline BAFF expression had significantly longer median progression-free survival (PFS) than those with high BAFF expression in patients with MM [28, 29], DLBCL [21], CTCL [17], and AML [30]. This evidence concerns the gene TNFSF13B and diffuse large B-cell lymphoma.